Welcome to our dedicated page for Nutra Pharma SEC filings (Ticker: NPHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
nutra pharma corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. the company carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. currently, nutra pharma offers several drug products for sale for the treatment of pain: nyloxin, the first over-the-counter (otc) pain reliever clinically proven to treat moderate to severe (stage 2) chronic pain, and nyloxin extra strength, the only non-narcotic and non-addictive treatment for severe (stage 3) pain. see: www.nyloxin.com nutra pharma also offers pet pain-away: a product aimed at treating moderate to severe chronic pain in companion animals. pet pain-away is specifically indicated to treat pain from hip dysplasia, arthritNutra Pharma Corp. filed its annual report detailing 2024 results and continued financial strain. The biopharmaceutical company markets homeopathic pain products like Nyloxin, Pet Pain-Away, Equine Pain-Away and Luxury Feet, and is developing drug candidates RPI-78M and RPI-MN for autoimmune, neurological and viral diseases.
Nutra Pharma reported a 2024 net loss of $1,285,663, following a 2023 net loss of $1,393,356, and disclosed material weaknesses in internal control over financial reporting. Management warns there is substantial doubt about its ability to continue as a going concern without new financing and higher product sales.
The company holds an FDA Orphan Drug Designation for RPI-78M in pediatric multiple sclerosis and aims to start Phase I/II trials in 2026, subject to funding. As of February 17, 2026, Nutra Pharma had 7,159,727,214 common shares and 12,000,000 Series B preferred shares outstanding, and reported non‑affiliate equity market value of $6,762,239 as of its most recent second quarter.
Nutra Pharma Corp. reports another quarterly loss and highlights serious financial strain in its Q3 2024 report. For the nine months ended September 30, 2024, net sales were $164,436 with additional related-party sales of $106,184, while the company recorded a net loss of $1,054,756, similar to the prior year’s loss. Gross profit fell compared with 2023 as operating expenses continued to exceed revenue.
The balance sheet shows total assets of $558,838 against total liabilities of $15,378,402, resulting in a stockholders’ deficit of $14,819,564. The company discloses that it had no cash at period-end, a working capital deficit of $14,902,502, and significant debt, much of it in default or convertible. Management states there is substantial doubt about its ability to continue as a going concern and notes that common stock trades on the OTC Expert Market, which limits capital-raising options.